EllumGet notified

What is Maridebart cafraglutide (MariTide)?

The short answer

Maridebart cafraglutide is a peptide joined to another molecule.

  • What it is

    Maridebart cafraglutide (MariTide): GIPR antagonist + GLP-1 agonist antibody-peptide conjugate.

  • What people look into

    Weight

By Ellum EditorialUpdated AI use

Get updates on Maridebart cafraglutide (MariTide)

What it is

Also known as
amg 133, cafraglutide

Regulatory status

Investigational (phase 3) How we label status

As of October 4, 2026, Maridebart cafraglutide (MariTide) is not FDA-approved for any use and is not on FDA's 503A bulks list. It is in phase 3 trials.

See Maridebart cafraglutide (MariTide) in the Index →

Federal (FDA)
Investigational, phase 3 (MARITIME), not filed
503A compounding
No category; not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026)

References

Sources as of October 4, 2026

  1. FDA: api.fda.gov/drug/drugsfda.json
  2. ClinicalTrials.gov: clinicaltrials.gov/study/NCT06858839
  3. eCFR: www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23